Abivax will present nine scientific abstracts on obefazimod at Digestive Disease Week 2026, highlighting Phase 3 data in ulcerative colitis as the French biotech seeks to strengthen the profile of its lead inflammatory bowel disease candidate.

The presentations, scheduled for the Chicago meeting on May 2-5, include efficacy, safety and patient-reported outcomes from the Phase 3 Abtect-1 and Abtect-2 induction trials in moderately to severely active ulcerative colitis.

The company is also due to present preclinical findings suggesting anti-fibrotic activity, broadening the potential scientific narrative around the drug beyond inflammation control.

Obefazimod is Abivax’s lead clinical asset and is being developed for patients with ulcerative colitis, a chronic inflammatory bowel disease that can require long-term treatment and multiple therapy switches when symptoms are not adequately controlled.

The most closely watched presentation is likely to be an oral session on May 4 covering histologic and combined histologic-endoscopic outcomes from the placebo-controlled induction studies. Such measures are closely followed by clinicians and regulators because they can indicate whether treatment is improving bowel tissue inflammation as well as visible disease activity.

Additional posters will focus on early symptomatic improvement, elderly patient outcomes, safety findings and performance in patients who previously had inadequate response to advanced therapies, including some with prior JAK inhibitor exposure.

Abivax is also highlighting quality-of-life measures, including fatigue and broader patient-reported outcomes. These endpoints have become increasingly important in ulcerative colitis drug development as companies try to show benefits beyond endoscopic remission.

Fabio Cataldi, chief medical officer of Abivax, said: “The data being presented at this conference reinforce our confidence in obefazimod as a meaningful advancement for patients living with ulcerative colitis.”

He added: “From histologic and endoscopic outcomes to patient-reported improvements in fatigue and quality of life, these abstracts paint a comprehensive picture of a therapy with potential to address what matters most to patients and clinicians alike.”

While the conference programme gives investors and clinicians a roadmap of what Abivax plans to showcase, detailed numerical results were not disclosed in the announcement.

That means attention will now turn to the DDW presentations themselves, where remission rates, response data, subgroup analyses and adverse event findings are expected to provide a clearer picture of how obefazimod could compete in a crowded ulcerative colitis market that already includes biologics, JAK inhibitors and newer targeted therapies.

Marc de Garidel, chief executive officer of Abivax, added: “Our presence at DDW with nine abstracts highlights the depth and growing strength of the obefazimod dataset we are building in inflammatory bowel disease.”

For Abivax, strong reception at DDW could help maintain momentum behind one of Europe’s more closely watched late-stage biotech programmes.